[go: up one dir, main page]

WO1995016037A1 - Anticorps monoclonal anti-egf-r/anti-cd3, a double specificite, procede de production et utilisation de cet anticorps - Google Patents

Anticorps monoclonal anti-egf-r/anti-cd3, a double specificite, procede de production et utilisation de cet anticorps Download PDF

Info

Publication number
WO1995016037A1
WO1995016037A1 PCT/EP1994/003995 EP9403995W WO9516037A1 WO 1995016037 A1 WO1995016037 A1 WO 1995016037A1 EP 9403995 W EP9403995 W EP 9403995W WO 9516037 A1 WO9516037 A1 WO 9516037A1
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibody
egf
dsm
hybridoma
bimab
Prior art date
Application number
PCT/EP1994/003995
Other languages
English (en)
Inventor
Antonio Mele
Rita De Santis
Cristina Ferrer Marsal
Original Assignee
Menarini Ricerche Sud S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Ricerche Sud S.P.A. filed Critical Menarini Ricerche Sud S.P.A.
Priority to AU12417/95A priority Critical patent/AU1241795A/en
Publication of WO1995016037A1 publication Critical patent/WO1995016037A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • Anti-EGF-R/anti-CD3 bispecific monoclonal antibody method for i ts production and its use .
  • the present invention relates to the construction of a hybrid hybridoma secreting a new anti-EGF-R/anti-CD3 bispecific monoclonal antibody (bimAb) of hybrid isotype ( IgGl/IgG2a) useful in tumor theraphy of cells showing the epidermal growth factor receptor (EGF-R+ ) .
  • bimAb bispecific monoclonal antibody
  • the present invention relates to such antibody and to i ts purification thereto .
  • Such purified antibody was able to trigger the lysis of EGF-R+ tumor cell lines (for example A431 , IGROV-1 , MDA-468 and U-87 ) and of NIH-3T3 transfectant cells expressing the human EGF-R , by cy-tolytic T lymphocytes , but it was uneffective on EGF-R- tumor targets ( where the signs + and - associated to EGF-R indicate respectively the presence or the absence of said receptor on cells ) .
  • Anti-tumor/anti-CD3 bispecific monoclonal antibodies are useful reagents able to confer anti-tumor specificity to T lymphocytes .
  • the authors of the present invention constructed a hybrid hybridoma secreting an anti-EGF-R/anti-CD3 bispecific monoclonal antibody (bimAb) and they compared such antibody to the above mentioned one (kindly provided by Dr.Ferrini and hereinafter named "Ferrini bimAb”) which, as far as the applicant knows, represents the only anti-EGF-R/anti-CD3 bimAb which has ever been disclosed.
  • bimAb anti-EGF-R/anti-CD3 bispecific monoclonal antibody
  • a fundamental characteristic of the present invention therefore refers to a hybrid hybridoma deposited at DSM (DSM ACC2151) and to the bispecific monoclonal antibody secreted by such hybrid hybridoma, and that is the anti-EGF-R/anti-CD3 bimAb of hybrid isotype (IgGl/IgG2a) hereinafter named DSM ACC2151 bimAb.
  • a further aspect of the present invention refers to the preparation of DSM ACC2151 hybrid hybridoma and to the recovery of bimAb secreted by said hybridoma.
  • a further characteristic of the present invention refers to the purification of such DSM ACC2151 bimAb by a Protein-A chromatography followed by a cation exchange chromatography.
  • the present invention also refers to anti-EGF-R (DSM ACC2150) and anti-
  • the present invention further refers to the production of a pharmaceutical composition comprising a monoclonal antibody or its fragments, for example F(ab' )2 fragment, according to the invention for the treatment of tumors, optionally in combination with a pharmaceutically acceptable carrier and/or excipient.
  • FIG. 1 shows the effect of DSM ACC2151 hybrid hybridoma supernatant on the cytolytic activity of CD3+8+ BC1 cytolytic clone against the EGF- R+ A431 target cell line in a 4-hour -> Cr-release test.
  • the ordinate reports the % of lysis of the target cells.
  • FIG. 2 shows the effect of different concentrations of the purified DSM ACC2151 bimAb on the cytolytic activity of a cytotoxic CD8+ polyclonal cell line against EGF-R+ normal and neoplastic target cells.
  • the abscissa reports in logarithmic scale the bimAb concentration (ng/ml).
  • the ordinate reports the % of lysis concentration of the target cells.
  • FIG. 3 shows the effect of DSM ACC2151 bimAb on the cytolytic activity of different populations of effector cells against the EGF-R+ A431 tumor cell line.
  • the abscissa reports the E:T ratio of effector cells/target cells.
  • the ordinate reports the % of lysis of target cells.
  • FIG. 4 shows the effect of DSM ACC2151 bimAb and DSM ACC2152 mAb on the intracellular free Ca concentration on CD8+ polyclonal cell lines.
  • panel A a rabbit anti-mouse Ig antibody was added as negative control.
  • panels B and C DSM ACC2152 mAb and DSM ACC2151 bimAb were respectively used, followed by the addition of anti-mouse Ig antiserum as cross-linking agent.
  • panel D cells were coated with DSM ACC2151 bimAb and cultured for 24 hours in the absence of soluble DSM ACC2151 bimAb. Before the experiment an anti-mouse IgG was added to the test. The ordinate reports the Ca concentration in nM.
  • FIG. 5 shows the capacity of effector cells coated with DSM ACC2151 bimAb to retain the ability to lyse EGF-R+ target cells for a prolonged time.
  • a CD8+ polyclonal cell line was coated with DSM ACC2151 bimAb (100 ng/ml for 1 hour at 4°C) and cultured for 24 hours in absence of soluble DSM ACC2151. Data are expressed as % of ⁇ Cr-release from A 31 target cells at a 10:1 effector/target cell ratio.
  • Figure 6 shows analytical MonoS chromatography (Pharmacia) of material eluted from Protein A chromatography of DSM ACC2151 hybrid hybridoma conditioned medium.
  • FIG. 7 shows analytical MonoS chromatography (Pharmacia) of DSM ACC2151 bimAb purified by cation exchange chromatography on S-Sepharose FF (Pharmacia) .
  • FIG. 8 shows an electrophoretic analysis by sodium dodecyl sulphate- polyacrilamide (SDS-PAGE) gel of purified fractions of DSM ACC2151 bimAb.
  • FIG. 9 shows the cytolytic activity of DSM ACC2151 bimAb if compared to that of Ferrini bimAb.
  • the abscissa reports, in logarithmic scale, the amounts expressed in ng/ml.
  • the ordinate reports the percentage of lysis according to an effector cells (lymphocytes)/target cells (tumor cells) ratio of 5/1.
  • SEQ ID NO:3 reports the oligonucleotide sequence of the light chain variable (VL) region of DSM ACC2152 mAb .
  • - SEQ ID NO : 5 reports the nucleotide sequence of the primer named VH1BACK Hindlll for use in PCR .
  • - SEQ ID NO : 6 reports the nucleotide sequence of the primer named VHFOR-LINKER SCA for use in PCR .
  • - SEQ ID NO : 7 reports the nucleotide sequence of the primer named VLBACK-LINKER SCA for use in PCR .
  • - SEQ ID NO : 8 reports a nucleotide sequence of the primer named VLFOR UNIVERSAL EcoRl for use in PCR .
  • the anti-EGF-R/anti-CD3 bispecific monoclonal antibody of IgGl/IgG2a hybrid isotype is secreted by a hybrid hybridoma obtainable by somatic hybridization of a hybridoma secreting an anti-EGF-R monoclonal antibody and a hybridoma secreting an anti-CD3 monoclonal antibody.
  • the method for the production of a hybrid hybridoma secreting an anti- EGF-R/anti-CD3 bispecific monoclonal antibody of IgGl / IgG2a hybrid isotype therefore comprises the somatic hybridization of a hybridoma secreting an anti-EGF-R monoclonal antibody and a hybridoma secreting an anti-CD3 monoclonal antibody .
  • the method for the production of an anti-EGF-R/ anti -CD3 bispecific monoclonal antibody comprises the somatic hybridization of a hybridoma secreting an anti-CD3 mAb and a hybridoma secreting an anti-EGF-R mAb , and then the purification of such antibody ( preferably , first by Protein-A chromatography and then by cation exchange chromatography) .
  • the bimAb according to the invention can be easily and efficiently purified from parental mAbs ( i . e . anti-CD3 mAb and anti-EGF-R mAb ) by Protein-A chromatography followed by cation exchange chromatography .
  • the hybridoma secreting the anti-EGF-R mAb is preferably the hybridoma named Mint5 (described in patent application PCT/EP94/02969 of the same applicant) and deposited as DSM ACC2150, while the hybridoma secreting the anti-CD3 mAb is preferably the hybridoma deposited as DSM ACC2152.
  • the bispecific antibody according to the invention can be obtained also in form of recombinant single chain by genie fusion of sequences of variable regions of the light and heavy chain of genes encoding an anti- CD3 monoclonal antibody and an anti-EGF-R monoclonal antibody, respectively, according to the known techniques.
  • Anti-CD3 mAb is preferably secreted by DSM ACC2152 hybridoma, while anti-EGF-R mAb is preferably secreted by DSM ACC2150 hybridoma.
  • the purified bimAb according to the invention was able to trigger the lysis of EGF-R+ tumor cell lines (for example A431, IGROV-1, MDA468, U- 87, etc.) and of NIH-3T3 trasnfectacts expressing human EGF-R by cytolytic T lymphocytes, but it was uneffective to stimulate the lysis of EGF-R- tumor targets.
  • EGF-R+ tumor cell lines for example A431, IGROV-1, MDA468, U- 87, etc.
  • NIH-3T3 trasnfectacts expressing human EGF-R by cytolytic T lymphocytes
  • Normal EGF-R+ cells keratinocytes and endometrial cells
  • the ability of the bimAb according to the invention to deliver activation signals to T cells was evaluated by Ca mobilization and lymphokine production experiments.
  • the bimAb according to the invention when administered in in vitro studies in soluble form, failed to induce an intracellular Ca increase, which occurred only after cross-linking induced by an anti-mouse IgG antibody (Fig.4).
  • Secretion of lymphokines IFN-ga ma, TNF- ⁇ and GM-CSF was induced only by contact of the bimAb coated effector cells with the specific tumor target, according to the invention.
  • the data hereinafter reported indicate that the bimAb according to the invention induce efficiently and specifically the secretion of lymphokines from T lymphocytes by contact with EGF-R+ tumor cells.
  • T lymphocytes coated with the bimAb according to the invention could be used, for example, for: a) local treatment of tumors expressing EGF-R molecules, provided that tissues surrounding the tumor are EGF-R-; or b) systemic treatment of tumors overexpressing EGF-R.
  • Peripheral blood mononuclear cells were isolated from 20 ml of p heparinized peripheral blood by centrifugation on Ficoll Hypaque density gradient. After three washes in RPMI 1640 medium (Seromed, Berlin, Germany) , supplemented with 10% heat-inactivated FCS (Fetal calf serum, PAA , Austria) , penicillin-streptomycin ⁇ 1% vol/vol of a commercial solution ; Seromed , Berlin , Germany ) and 200 mM L-Glutamin ( complete medium) cells were resuspended in the same medium and brought to the concentration of 10 /ml .
  • FCS Fetal calf serum, PAA , Austria
  • T lymphoblasts for immunization were produced by culture for 3 days in complete medium with 1% vol/vol PHA (Phytohemagglutin, Gibco, NY, USA) and cultured 3 days in 24 well Costar plates . Lymphoblasts were then expanded by culture in complete medium supplemented with 50 Ul/ml of recombinant IL2 (Cetus Corporation, CA, USA) . Immunization fusion and screening
  • mice Six-week-old Balb/c female mice were immunized by four weekly intraperitoneal injections of 10 ' cultured lymphoblasts obtained by culture as in the previous step. T lymphoblasts from different cultures were pooled together and washed two times in PBS and resuspended in 0.2 ml PBS for injection. After 10 days mice received a booster injection of 10 ' cells , followed by splenectomy 3 days later . The spleen was
  • HAT Hypoxantine Aminopterine Thymidine
  • the amplified variable regions were cloned in the Hindlll-EcoRI restriction sites of pUCl ⁇ plasmid for sequencing. To introduce Hindlll and EcoRI restriction sites in the variable regions, they were reamplified and linked together according to Davis et al. , 1991. Bio/Technology 9. I65-I69. using the following primers: 5'VH: VH1BACK Hindlll: (SEQ ID NO: ) 3'VH: VHF0R-LINKER SCA: (SEQ ID NO:6) 5'VL: VLBACK-LINKER SCA: (SEQ ID N0:7) 3'VL: VLFOR UNIVERSAL EcoRl: (SEQ ID NO:8)
  • DSM ACC2152 mAb VH nucleotide is reported in SEQ ID N0:1.
  • DSM ACC2152 mAB VL nucleotide is reported in SEQ ID NO:3- The DSM ACC2152 VH and VL DNA sequences were analyzed for homology against PCgene data base (Intelligentics 1992) and were confermed as new sequences (being not present in the data bank) .
  • Example 2
  • Mint-5 ( IgGl ) anti-EGF-R hybridoma (described in the copending patent application PCT/EP94/02969 of the same applicant) was deposited as DSM ACC2150.
  • DSM ACC2150 and DSM ACC2152 hybridomas were used for the preparation of a hybrid hybridoma named B/MRS 26.1.17 deposited as DSM ACC2151 secreting the bimAb of interest.
  • Hypoxantineguanine phosphoribosyltransferase (HGPRT)-deficient mutants of the DSM ACC2150 hybridoma were selected by culture in the presence of increasing amounts of 8-azaguanine (1-50 ⁇ g/ml) (Sigma, St.Louis, M0).
  • Hybrid hybridomas (quadromas) were selected by culture in HAT medium. Hybrid hybridomas were cloned by limiting dilution and tested for antibody production.
  • the culture medium for hybrid hybridomas was RPMI 1640 supplemented with 10% FCS and 2mM L- glutamine.
  • the hybrid hybridoma supernatants were directly screened for their ability to induce the CD8+ cytolytic T cell clone BC1 to lyse the EGF-R+ A431 tumor target cells (Merlino et al., 1984, Science, 224, 4l7 ⁇ 419). As shown in Figure 1, a 1:100 dilution of the supernatant of the selected hybrid hybridomas, the DSM ACC2151 secreting the bimAb, efficiently induced lysis of the A431 target cells. Parental anti-CD3 anti-EGF-R mAbs used alone or in combination failed to induce A431 cell lysis.
  • T cell lines and clones were used as effector cells at effector/target cell ratio ranging from 40:1 to 0.6:1 in a 4h ⁇ C-release assay.
  • the following cell lines were used as targets: IGROV-1 (ovarian carcinoma), MeWo (melanoma), Raij (Burkitt's lymphoma) , MDA-468 (breast cancer), A431 (epidermoid carcinoma), U-87 (glioma) , NIH-3T3 and NIH-3T3 EGF-R+ transfectants (kindly provided by Dr. P. Di Fiore, NIH, Bethesda, MD; Di Fiore et al.
  • the percentage of lysis was calculated as described in Ferrini et al., 1987. J. Immunol., 138, 1297- 1302. To verify the target specificity, the bimAb DSM ACC2151 was tested for its ability to induce cytolysis of EGF-R+ and EGF-R- tumor target cells,
  • EGF-R+ cell lines EGF-R+ cell lines
  • EGF-R- cell lines EGF-R- cell lines
  • Analysis of both EGF-R+ normal cells (keratinocytes and endothelial cells) required higher amounts of bimAb for half-maximal cytolysis being ED50 12 and 100 ng/ml, respectively, as compared with A431 cells ( Figure 2).
  • EGF-R- PHA-induced lymphoblasts were not lysed in the presence of DSM ACC2151 bimAb.
  • CD4+, CD8+ or TCRgamma/ ⁇ + T lymphocytes were mitogen-activated and expanded for 2-3 weeks in IL-2 containing medium. It was observed that lysis of A431 target cells could be induced by PHA-activated IL-2 expanded T lymphoblasts but not by resting PBL. Both CD8+ and TCRgamma/ ⁇ + cells efficiently lysed A431 in the presence of DSM ACC2151 bimAb, while CD4+ cells were poorly effective (Figure 3) ⁇ Similar results were obtained using PBL and purified populations isolated from three additional healthy donors.
  • the level of cytolytic activity induced by DSM ACC2151 bimAb varied among effector cell populations obtained from the different donors.
  • the cytolytic activity of four different CD3+CD8+ populations against A431 cells ranged from 45 to 70% of 3 Cr release at a 10:1 effector to target cell ratio.
  • the concentration of cytoplasmic free Ca++ was determined in CD8+ polyclonal cell lines as described previously by Pantaleo et al., 1986, Eur. J. Immunol., 16, l639 ⁇ l644.
  • Cells (2.5 10°) were stained with the acetoxymethylester of Fura-2 (1 uM final concentration; Sigma, St. Louis, MO, USA) , and the fluorescence of the cellular suspension was monitored with Spectrofluorimeter (Perkin Elmer Corp., Pomona, CA, USA) using a 2 ml quartz cuvette. Cell suspensions were excited at 345 nm and fluorescence was measured at 4 6 nm.
  • Effector cells were stimulated with target cells, with parental antibodies or DSM ACC2151 bimAb in different combination.
  • soluble anti-CD3 mAb plus 2 ng/ml of phorbol 1,2-myristate-l,3 ⁇ acetate (PMA) were used as a positive control.
  • PMA phorbol 1,2-myristate-l,3 ⁇ acetate
  • GM-CSF, IFN-gamma and TNF- ⁇ were measured using the EASIA kits (Enzyme Amplified Sensitivity Immunoassay, Medgenix Diagnostics, Brussels, Belgium) following instructions supplied by the manufacturer.
  • anti-CD3 was able to induce secretion of IFN-gamma, TNF- ⁇ and GM-CSF in polyclonal T cell lines in the presence of phorbol esther PMA as a co-stimulus .
  • EGF-R+ tumor cells were added to untreated lymphocytes , only low levels of lymphokine secretion could be achieved, while maximal lymphokine production was induced by the simultaneous use of bimAb and relevant target cells .
  • EGF-R- tumor cell lines and bimAb did not induce significant lymphokine secretion.
  • DSM ACC2151 bimAb represented only a fraction of the antibody molecules secreted by hybrid hybridomas ( Milstein and Cuello , 1984 , Immunol . Today, 5 , 299-304) , the present authors purified the DSM ACC2151 bimAb by protein A chromatography followed by cation exchange chromatography . DSM ACC2151 bimAb was purified from hybrid hybridoma culture supernatant . Cells producing bimAb were grown in serum- free medium in Acusyst R hollow fiber bioreactor (Endotronics) .
  • Protein A binding buffer 1.5 M glycine pH 8.9; 150 mM NaCl
  • Protein A elution buffer is: 0.1 M sodium citrate pH 3-6.
  • Eluted material from Protein A was analyzed by MonoS chromatography as reported in Figure 6 showing the presence of DSM ACC2151 bimAb distributed in two peaks (1 and 2) and the presence of parental ⁇ CD3 DSM ACC2152 and ⁇ EGF-R DSM ACC2150 mAbs.
  • eluted material from Protein A was diluted 1:1 in buffer A (25 mM sodium acetate pH 5-0) and located on xk 26 column of S-Sepharose FF (Pharmacia) conditioned with buffer A plus 50 mM NaCl. Elution was performed by a step procedure with buffer B made of buffer A plus 1 M NaCl. The steps were 20%, 25% and 30% of buffer B. Fractions from S-Sepharose chromatography were analyzed by MonoS chromatography and fractions corresponding to peak 1 of Figure 6 were pooled and confirmed to be DSM ACC2151 bimAb according to IEF pattern and functional activity.
  • Figure 7 shows the analytical MonoS chromatography of purified DSM ACC2151 bimAb. Purity was further confirmed by SDS-PAGE analysis on Phast gel 4-15% (Pharmacia) ( Figure 8) .
  • Figure 8 shows a SDS-PAGE analysis exhibiting the electrophoretic mobility in both reducing and non-reducing conditions.
  • Lane 3 contains parental ⁇ CD3 mAb and lanes 4 and 5 contain ⁇ EGF-R and ⁇ CD3 standard in mAbs.
  • the presence of the highest concentration of bifunctional molecules of bimAb DSM ACC2151 in purified peak 1 was confirmed by cytolitic assay against A431 target cells. Comparison of the DSM ACC2151 bimAb activity with the Ferrini bimAb activity
  • DSM ACC2151 bimAb was prepared and purified as above described.
  • Ferrini bimAb was obtained by Dr. Ferrini (as previously specified).
  • the activity of the two anti-EGF-R/anti-CD3 bimAbs was analysed testing the cytolitic activity of a CD8+ cytolitic cell line against A431 target cells in the presence of different concentrations of bimAb.
  • DSM ACC2151 bimAb was significatively stronger to induce cytolitic activity at low concentration of bimAb if compared to Ferrini bimAb.
  • IC50 calculated for the two bimAbs (Fig.9) shows that DSM ACC2151 bimAb is about 10 times more active than Ferrini bimAb. According to the evaluation of the activities of the above cited bimAbs, then it results surprising the different behaviour (that maybe could indicate a different mechanism of action) of the two bimAbs studied.
  • a DNA sequence coding for an antibody according to the invention can be prepared. Said sequence, eventually, can be inserted into a plasmid vector, preferably under the control of a promoter which enables its expression in a desired host cell.
  • Said host cell is selected from the group consisting of bacterial, yeast, insect, plant or mammalian cells.
  • the present invention is therefore directed also to a method for the production of a monoclonal antibody or fragments thereof according to the invention comprising the cultivation of a host cell under conditions appropriate for the expression of said DNA sequence and recovering the product from the culture.
  • An antibody according to the present invention is also useful in theraphy.
  • An antibody or its fragments [for example F(ab')2_ according to the invention is also used for the preparation of a pharmaceutical composition, useful for the treatment of tumors, in combination with a pharmaceutically acceptable carrier and/or excipient.
  • a pharmaceutical composition according to the present invention therefore comprises a monoclonal antibody or its fragments according to the invention for the treatrement of tumors , optionally in combination with a pharmaceutically acceptable carrier and/or excipient .

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention se rapporte à un anticorps monoclonal à double spécificité (bimAb) anti-EGF-R (récepteur du facteur de croissance de l'épiderme)/anti-CD3, appartenant à un isotype hybride (IgG1/IgG2a). L'invention se rapporte également à la production d'un hybridome hybride sécrétant un tel anticorps bimAb, ainsi qu'à la purification de molécules d'anticorps bimAb anti-EGF-R/anti-CD3, à partir d'hydribomes hybrides, par chromatographie à échange de cations et sur protéine A. De tels anticorps bimAb se sont révélés aptes à détruire les cellules tumorales présentant le récepteur du facteur de croissance de l'épiderme (EGF-R+).
PCT/EP1994/003995 1993-12-01 1994-12-01 Anticorps monoclonal anti-egf-r/anti-cd3, a double specificite, procede de production et utilisation de cet anticorps WO1995016037A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU12417/95A AU1241795A (en) 1993-12-01 1994-12-01 Anti-egf-r/anti-cd3 bispecific monoclonal antibody, method for its production and its use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITFI930246A IT1271461B (it) 1993-12-01 1993-12-01 Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
ITFI93A000246 1993-12-01

Publications (1)

Publication Number Publication Date
WO1995016037A1 true WO1995016037A1 (fr) 1995-06-15

Family

ID=11350667

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/003995 WO1995016037A1 (fr) 1993-12-01 1994-12-01 Anticorps monoclonal anti-egf-r/anti-cd3, a double specificite, procede de production et utilisation de cet anticorps

Country Status (3)

Country Link
AU (1) AU1241795A (fr)
IT (1) IT1271461B (fr)
WO (1) WO1995016037A1 (fr)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712136A (en) * 1994-09-08 1998-01-27 Genvec, Inc. Adenoviral-mediated cell targeting commanded by the adenovirus penton base protein
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6018031A (en) * 1989-10-20 2000-01-25 Trustees Of Dartmouth College Binding agents specific for IgA receptor
US6057155A (en) * 1995-11-28 2000-05-02 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
RU2170257C2 (ru) * 1994-03-17 2001-07-10 Мерк Патент Гмбх Анти-эфрр одноцепочечный fv, химерное анти-эфрр антитело и способ его получения, фармацевтическая композиция для лечения опухолей, средство для диагностики локализации или оценки роста опухоли
EP1417232A4 (fr) * 2001-06-13 2005-04-27 Genmab As Anticorps monoclonaux humains diriges contre le recepteur de facteur de croissance epidermique (egfr)
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6951755B2 (en) 1994-09-08 2005-10-04 Genvec, Inc. Vectors and methods for gene transfer
US7052881B2 (en) 1995-06-15 2006-05-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO2006125599A2 (fr) 2005-05-25 2006-11-30 F. Hoffmann-La Roche Ag Methode de purification d'anticorps
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
US7250293B2 (en) 1999-05-18 2007-07-31 Crucell Holland B.V. Complementing cell lines
WO2008145351A1 (fr) 2007-06-01 2008-12-04 F. Hoffmann-La Roche Ag Purification d'une immunoglobuline
US7468181B2 (en) 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7635475B2 (en) 2003-02-17 2009-12-22 Tohoku Techno Arch Co., Ltd. Diabody-type bispecific antibody
WO2010072381A1 (fr) 2008-12-22 2010-07-01 F. Hoffmann-La Roche Ag Purification d'immunoglobuline
US7749493B2 (en) 1998-07-08 2010-07-06 Crucell Holland B.V. Chimeric adenoviruses
CN101307109B (zh) * 2008-06-04 2010-11-17 张传林 鼠抗人t淋巴细胞cd3表面抗原单克隆抗体及其制备方法和用途
US20130129729A1 (en) * 2005-10-11 2013-05-23 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
US9884921B2 (en) 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
US20200095319A1 (en) * 2007-04-03 2020-03-26 Amgen Research (Munich) Gmbh Cross-species-specific bispecific binders
US10669337B2 (en) 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
US11161906B2 (en) 2013-07-25 2021-11-02 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
WO2022074206A1 (fr) 2020-10-08 2022-04-14 Affimed Gmbh Lieurs trispécifiques
US11472889B2 (en) 2017-10-14 2022-10-18 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
WO2023007023A1 (fr) 2021-07-30 2023-02-02 Affimed Gmbh Corps duplex

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
D. MEZZANZANICA ET AL.: "Use of bispecific mAbs, anti-CD3/anti-EGF-R, to retarget human activated T lymphocytes against tumor cells over-expressing EGF-R.", THE FASEB JOURNAL, vol. 6, no. 5, 28 February 1992 (1992-02-28), BETHESDA MD, USA, pages A2059 *
E. TOSI ET AL.: "The anti-EGFR MINT5 mAb is able to specifically target RIP alpha-sarcin cytotoxicity against relevant target cells.", EUROPEAN JOURNAL OF CANCER, vol. 27, no. SUP3, 1991, OXFORD, GB, pages S57 *
M. SHALABY ET AL.: "Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene.", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 175, January 1992 (1992-01-01), NEW YORK NY, USA, pages 217 - 225 *
S. FERRINI ET AL.: "Targeting of T lymphocytes against EGF-receptor+ tumor cells by bispecific monoclonal antibodies: Requirement of CD3 molecule cross-linking for T cell activation.", INTERNATIONAL JOURNAL OF CANCER, vol. 55, no. 6, 2 December 1993 (1993-12-02), GENEVA, SWITZERLAND, pages 931 - 937 *
S. FERRINI ET AL.: "Targeting of T lymphocytes by anti-CD3/anti-EGF-R bispecific monoclonal antibodies. Role of adhesion molecules.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 34, March 1993 (1993-03-01), USA, pages 476 *
S. FERRINI ET AL.: "Targeting of T or NK lymphocytes against tumor cells by bispecific monoclonal antibodies: Role of different triggering molecules.", INTERNATIONAL JOURNAL OF CANCER, SUPPLEMENT, vol. 7, 1992, GENEVA, SWITZERLAND, pages 15 - 18 *
S. FERRINI ET AL.: "Use of anti-CD3 and anti-CD16 bispecific monoclonal antibodies for the targeting of T and NK cells against tumor cells.", CANCER DETECTION AND PREVENTION, vol. 17, no. 2, 1993, NEW YORK NY, USA, pages 295 - 300 *
S. GILLIES ET AL.: "Targeting human cytotoxic T lymphocytes to kill heterologous epidermal growth factor receptor-bearing tumor cells.", THE JOURNAL OF IMMUNOLOGY, vol. 146, no. 3, 1 February 1991 (1991-02-01), BALTIMORE MD, USA, pages 1067 - 1071 *

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018031A (en) * 1989-10-20 2000-01-25 Trustees Of Dartmouth College Binding agents specific for IgA receptor
RU2170257C2 (ru) * 1994-03-17 2001-07-10 Мерк Патент Гмбх Анти-эфрр одноцепочечный fv, химерное анти-эфрр антитело и способ его получения, фармацевтическая композиция для лечения опухолей, средство для диагностики локализации или оценки роста опухоли
US6951755B2 (en) 1994-09-08 2005-10-04 Genvec, Inc. Vectors and methods for gene transfer
US5712136A (en) * 1994-09-08 1998-01-27 Genvec, Inc. Adenoviral-mediated cell targeting commanded by the adenovirus penton base protein
US6153435A (en) * 1995-02-21 2000-11-28 Cornell Research Foundation, Inc. Nucleic acid that encodes a chimeric adenoviral coat protein
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US7105346B2 (en) 1995-06-15 2006-09-12 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7052881B2 (en) 1995-06-15 2006-05-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6057155A (en) * 1995-11-28 2000-05-02 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6329190B1 (en) 1995-11-28 2001-12-11 Genvec, Inc. Targetting adenovirus with use of constrained peptide motifs
US6649407B2 (en) 1995-11-28 2003-11-18 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6303755B1 (en) 1996-07-11 2001-10-16 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-FCA receptor antibodies
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6193966B1 (en) 1996-07-11 2001-02-27 Mederax, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US7749493B2 (en) 1998-07-08 2010-07-06 Crucell Holland B.V. Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US7906113B2 (en) 1999-05-18 2011-03-15 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US7250293B2 (en) 1999-05-18 2007-07-31 Crucell Holland B.V. Complementing cell lines
US7270811B2 (en) 1999-05-18 2007-09-18 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
US9228205B2 (en) 2000-11-15 2016-01-05 Crucell Holland B.V. Complementing cell lines
US7344883B2 (en) 2000-11-15 2008-03-18 Crucell Holland B.V. Complementing cell lines
US9458236B2 (en) 2001-06-13 2016-10-04 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7247301B2 (en) 2001-06-13 2007-07-24 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US8586041B2 (en) 2001-06-13 2013-11-19 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP1417232A4 (fr) * 2001-06-13 2005-04-27 Genmab As Anticorps monoclonaux humains diriges contre le recepteur de facteur de croissance epidermique (egfr)
US7468181B2 (en) 2002-04-25 2008-12-23 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US7635475B2 (en) 2003-02-17 2009-12-22 Tohoku Techno Arch Co., Ltd. Diabody-type bispecific antibody
EP2261252A2 (fr) 2005-05-25 2010-12-15 F. Hoffmann-La Roche AG Méthode de purification d'anticorps
WO2006125599A2 (fr) 2005-05-25 2006-11-30 F. Hoffmann-La Roche Ag Methode de purification d'anticorps
US11925684B2 (en) 2005-10-11 2024-03-12 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
US20130129729A1 (en) * 2005-10-11 2013-05-23 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
US20200095319A1 (en) * 2007-04-03 2020-03-26 Amgen Research (Munich) Gmbh Cross-species-specific bispecific binders
WO2008145351A1 (fr) 2007-06-01 2008-12-04 F. Hoffmann-La Roche Ag Purification d'une immunoglobuline
CN101307109B (zh) * 2008-06-04 2010-11-17 张传林 鼠抗人t淋巴细胞cd3表面抗原单克隆抗体及其制备方法和用途
US9631008B2 (en) 2008-12-22 2017-04-25 Hoffmann-La Roche Inc. Immunoglobulin purification
WO2010072381A1 (fr) 2008-12-22 2010-07-01 F. Hoffmann-La Roche Ag Purification d'immunoglobuline
US11161906B2 (en) 2013-07-25 2021-11-02 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
US9884921B2 (en) 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
US10669337B2 (en) 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
US11802158B2 (en) 2014-07-25 2023-10-31 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
US11472889B2 (en) 2017-10-14 2022-10-18 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
US11859010B2 (en) 2017-10-14 2024-01-02 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
WO2022074206A1 (fr) 2020-10-08 2022-04-14 Affimed Gmbh Lieurs trispécifiques
WO2023007023A1 (fr) 2021-07-30 2023-02-02 Affimed Gmbh Corps duplex

Also Published As

Publication number Publication date
AU1241795A (en) 1995-06-27
ITFI930246A0 (it) 1993-12-01
ITFI930246A1 (it) 1995-06-01
IT1271461B (it) 1997-05-28

Similar Documents

Publication Publication Date Title
WO1995016037A1 (fr) Anticorps monoclonal anti-egf-r/anti-cd3, a double specificite, procede de production et utilisation de cet anticorps
US12291561B2 (en) Antigen binding receptors specific for mutated Fc domains
US6410690B1 (en) Therapeutic compounds comprised of anti-Fc receptor antibodies
AU2017316255C1 (en) Anti-PD1 monoclonal antibody, pharmaceutical composition thereof and use thereof
EP2970512B1 (fr) Protéines de fusion immunomodulatrices et leurs procédés de fabrication
EP0637593B1 (fr) Molécules de déclenchement bispécifiques pour reconnaítre l'antigène lymphocytaire CD2 et des antigènes tumorales
CA2255826C (fr) Domaines d'igg2 mutants et non activants et anticorps anti-cd3 les comprenant
EP1775307B1 (fr) Anticorps anti-CD3 utilisé pour l'induction d'immunosuppression
KR20190133017A (ko) 개선된 항원 결합 수용체 구성
JP2004516034A (ja) 抗−ｃｄ２８抗体
JP2002521053A (ja) ヘテロミニ体
CA2174132A1 (fr) Antagonistes de fas et leurs applications
JP2020530306A (ja) 多重特異性抗体とその作製及び使用方法
WO2007108152A1 (fr) Anticorps bispecifique hautement fonctionnel
KR20200092301A (ko) 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
TW202227503A (zh) 改良之抗原結合受體
CN116234831A (zh) 改善的抗原结合受体
US20220251154A1 (en) Fusion protein and use thereof
JP2022521958A (ja) 抗ｐｄ－ｌ１抗体及びその応用
CN113891718A (zh) 人工免疫监视嵌合抗原受体(ai-car)及其表达细胞
CN111344019A (zh) 调节免疫检查点作为癌症治疗的单特异性与双特异性蛋白质
CN118302443A (zh) 改善的抗原结合受体
CN118562015B (zh) 一种针对cd20/cd3的双特异性抗体及其制备方法和应用
JP7278623B2 (ja) 抗ｃｄ２７抗体およびその使用
EP0503646A1 (fr) Anticorps monocloneaux dressés contre l'antigène-3 associé à la fonction lymphocyte

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KE KG KP KR KZ LK LR LT LV MD MG MN MW NO NZ PL RO RU SD SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA